The Bull Rankings scorecard — our quality-growth score is 43.6 / 100, built from three pillars scored 0–100: Quality 66, Growth 50, Value 29 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 44% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Cameco isn’t cheap, but the market isn’t pricing in a uranium renaissance—it’s pricing in a uranium oligopoly. Our model gives it a 43.6/100 quality-growth score, with Quality at 66 and Value at 29, the weakest pillar by far. That imbalance tells the story: this is a high-quality compounder where durability trumps bargain hunting. The stock trades at 184.4x trailing earnings, a multiple that only makes sense if the uranium cycle isn’t just turning—it’s locking in for a decade. Revenue grew 11% year-over-year in the quarter ended 2025-12-31, yet the market is pricing in 44% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten). That’s not a bet on next year’s spot price; it’s a bet on Cameco’s control over the entire nuclear fuel chain—from mine to reactor—before the rest of the world catches up.
What the business actually is
Cameco sells nuclear fuel, not reactors, but it owns the critical middle of the chain. The Uranium segment mines, mills, and sells uranium concentrate to utilities and fuel fabricators. The Fuel Services segment refines, converts, and fabricates uranium into fuel assemblies, while also trading conversion services. The Westinghouse segment—the crown jewel—isn’t just a reactor supplier; it’s the OEM that keeps aging fleets running, providing outage support, engineering, and maintenance to commercial utilities and government agencies across three continents. When a nuclear plant needs fuel, parts, or a fix, Cameco is often the first call. That’s not a commodity business. It’s a bottleneck business.
Why it can (or can't) keep compounding
The moat isn’t in the ground—it’s in the permits, the reactors, and the relationships. Cameco’s profit margin of 16.9% in the latest quarter suggests the Fuel Services and Westinghouse segments are pulling their weight. The debt-to-equity of 0.17 means the balance sheet won’t choke growth when spot prices spike. Our model flags “cyclical growth (caution)”, but that’s not a death sentence—it’s a reminder that Cameco’s growth rides the uranium cycle, which is why the growth score is capped. The Westinghouse segment, in particular, benefits from long-term contracts with utilities that can’t afford downtime. A rival can build a mine, but replicating Cameco’s reactor service network takes decades. That’s the moat: not just owning uranium, but owning the infrastructure that turns it into electricity.
The valuation question
The market isn’t just pricing in growth—it’s pricing in a takeover of the uranium market. Our reverse DCF says today’s price implies ~44% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten), a figure that towers over the 11% revenue growth reported in the quarter ended 2025-12-31. That’s optimism baked in, not pessimism. The P/E of 184.4x isn’t a valuation error—it’s a bet that Cameco’s Westinghouse segment will lock in decades of high-margin service contracts while its uranium mines and fuel plants become the default supplier for a global nuclear buildout. If that happens, the multiple is justified. If it doesn’t, the stock is priced far ahead of the business.
The bear case
The weakest pillar in our model is Value at 29, and the numbers back it up. A P/E of 184.4x only works if uranium prices stay elevated and utilities keep signing long-term contracts. But uranium’s spot price is volatile, and a single policy shift—say, a slowdown in reactor restarts in Japan or Europe—could crater demand. The PEG ratio of 1.92 suggests the growth is expensive even after accounting for how fast analysts expect earnings to rise. If Cameco’s free cash flow stalls, the stock could quickly reprice to a more pedestrian multiple. The bear case isn’t that Cameco fails—it’s that the market’s optimism outpaces reality.
What would change our mind
Three things would flip the thesis. First, if the profit margin drops below 15%, the moat starts to erode, and the premium multiple loses justification. Second, if the debt-to-equity ratio rises above 0.25, the balance sheet risk becomes material on top of the cyclical risk. Third, if the analyst target range’s midpoint falls below $100, analysts are no longer pricing in a uranium oligopoly—they’re pricing in a uranium correction. Until then, Cameco remains a high-quality compounder, not a value play.